Arrowhead Pharmaceuticals (ARWR) vs Belite Bio (BLTE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Belite Bio (BLTE) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 5.7% versus a gain of 2.3%. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $5.17 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | BLTE |
|---|---|---|
| Share price | $41.37 | $127.38 |
| Market cap | $5.85B | $5.17B |
| 1-day change | -5.22% | -15.65% |
| YTD return | -37.69% | -20.37% |
| 1-year return | +2.27% | +5.66% |
| 5-year return | -42.56% | — |
| EPS (TTM) | $-5.11 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $450.82M | — |
| Revenue growth (YoY) | -45.65% | — |
| Net income (latest FY) | $-724.21M | $-77.61M |
| Operating margin | -156.86% | — |
| Net margin | -160.64% | — |
| 52-week high | $95.49 | $200.00 |
| 52-week low | $40.43 | $115.41 |
| Distance from 52-week high | -56.68% | -36.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +156.39% | +82.92% |
| Average volume | 2.08M | 195.65K |
| Shares outstanding | 141.37M | 40.61M |
| Employees | 1,062 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
ARWR vs BLTE FAQ
Which is bigger, Arrowhead Pharmaceuticals or Belite Bio?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $5.17B for Belite Bio (BLTE).
Which stock has performed better over the past year, ARWR or BLTE?
BLTE returned +5.66% over the past 12 months, compared with +2.27% for ARWR (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Belite Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.